7 results
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... #Candidiasis #candida ... #mucosal #IDSA ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
IDSA Recommendations ... with ARV (see Table ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Varicella Zoster Virus (VZV) Infections in HIV-AIDS
Pre-Exposure Prevention of VZV
IDSA Recommendations ... health-care provider diagnosis ... Uncomplicated Cases ... opportunistic #infections #HIVAIDS ... #pharmacology
Diuretics and Agents Regulating Renal Excretion

Carbonic Anhydrase Inhibitors (Acetazolamide, Dichlorphenamide)
 • Glaucoma
 • Epilepsy
 • Altitude
disequilibrium syndrome • Diagnosis ... Kidney stones caused ... Tolvaptan) • Treatment ... Diuresis #Nephrology #Pharmacology ... #Medications #Table
Candida Glabrata
Species of Candida Most Commonly Isolated in Bloodstream Infections
 • Symptomatic mucosal infection is detected
oropharyngeal, esophageal ... antibacterial medications ... infections include rare cases ... Treatment: • Exhibits ... CGlabrata #candidemia #diagnosis
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... and molecular diagnostic ... Please refer to the table ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
IDSA Recommendations ... please refer to Table ... #Prevention #Treatment ... opportunistic #infections #HIVAIDS ... #pharmacology